Crunching numbers to save lives around the world.
Support mathematical modelling at Burnet and help save lives around the world.
Support mathematical modelling at Burnet and help save lives around the world.
Support mathematical modelling at Burnet and help save lives around the world.
Support mathematical modelling at Burnet and help save lives around the world.
Over the past decade anti-HIV drugs have dramatically improved the prognosis for HIV infected individuals, yet achieving better access to vulnerable populations remains a challenge. The principal obstacle to the anti-HIV drug “maraviroc” from being more widely used in anti-HIV therapy regimens is that the pre-treatment in silico tests to determine virus susceptibility to maraviroc have been developed primarily for HIV subtype B strains, which account for only 10% of infections worldwide. We therefore developed PhenoSeq, a suite of highly accurate in silico tests for all of the major HIV subtypes, namely subtypes A, B, C, D, CRF01_AE and CRF02_AG, which together account for 95% of HIV-1 infections worldwide. PhenoSeq will inform the appropriate use of maraviroc in regions of the world where non-B HIV predominates, which are burdened the most by the HIV-1 pandemic.
The PhenoSeq platform comprises a suite of subtype specific V3 sequence-based genotypic tropism tests, designed specifically to predict the coreceptor usage of HIV-1 subtype A, B, C, D, CRF01_AE and CRF02_AG viruses.
To access PhenoSeq click here.
For any general enquiries relating to this facility, please contact:
Facilities Officer